A rat study found higher midazolam exposure after vonoprazan, providing an interaction signal rather than a human dosing rule.
The researchers tested metabolic inhibition in rat liver microsomes and compared probe-drug pharmacokinetics in treated and control rats. Midazolam exposure increased, while apparent oral clearance declined and time to peak increased. Other probe drugs showed different patterns.
After oral dosing, apparent clearance includes bioavailability; a change cannot automatically be assigned solely to liver elimination. Rat enzyme activity, experimental dosing, and small groups also limit translation. The paper did not demonstrate the size of a human midazolam interaction at ordinary therapeutic vonoprazan exposure. It is useful for identifying a potential pathway that deserves attention, but an individual clinical conclusion still requires actual medication timing, exposure, and response. Other benzodiazepines cannot be assumed to behave identically.
Original analysis of the supplied journal article, identified as PMC7033572.